Astronomers capture image of new comet 3I/ATLAS
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
‘What The Hell Just Happened?' Pete Davidson Recalled The Wild Story Behind How An Eye-Related Shot In New Horror Movie Could Have Caused ‘Real Damage'
When you buy through links on our articles, Future and its syndication partners may earn a commission. We've come a long way with movie magic. CGI technology and filmmaking techniques have made anything on the big screen possible. However, occasionally directors decide to go the practical route, as sometimes technology doesn't capture a moment the same way tangible effects do. This was the case in Pete Davidson's upcoming horror movie, The Home, where director James DeMonaco decided to use Davidson's actual eye for one of the freakest scenes in the film, and things almost got dangerous. The SNL alum recently sat down with Jimmy Fallon on The Tonight Show, and he talked about becoming a dad for the first time, as well as making The Home with the team that made The Purge. One of the scenes that is teased in the trailer features Davidson tied to a chair with a contraption holding his eye open, reminiscent of the famous eye scene in A Clockwork Orange. When the actor read the script, he naturally assumed that movie magic and new tech would be used to create this moment. He said: Obviously, I read the script and was like, 'That won't be my eye. This is the movies! It'll be a CGI eye.' If you can bring people back from the dead and put them in a movie, then that's not my eye. He has a great point. If movies can use motion capture to make actors into aliens for Avatar and dinosaurs come to life in Jurassic Park, they should realistically be able to digitally put Davidson's eye in a contraption just by using some green stickers and VFX post-production work. However, DeMonaco had other plans, and instead employed three doctors to be present while they actually put Davidson's eye in some monstrous contraption. The King of Staten Island star was understandably shocked by the idea, saying: So I get to set, and there's three doctors there, and they all look, you know, not – they're a little concerned. I'm like, 'What's going on?' and my buddy James [DeMonaco], the director, goes, 'They're here for your eye.' I was like, 'What do you mean?' Apparently, DeMonaco thought Davidson's eyes were just too distinctive to be recreated digitally, and the shot wouldn't be believable without using his actual eye. The whole thing became worse when Davidson's co-star had a hard time getting his lines right and made the situation go on longer than it should have. Eventually, one of the doctors had to step in to prevent any actual damage being done to their leading man's vision. The actor recalled: I heard, in the corner, one of the doctors went to the director and goes, 'Yeah, in about 30 more seconds there's gonna be some real damage.' So I take the thing off. I'm like squirting it with water and stuff. I'm like, 'What the hell just happened?' And then we're watching it in video village and the director goes, 'Yeah, it didn't have to be your eye.' Clearly, this was a case of a director being a little overzealous when it came to realism in movies. However, I do think the film benefits from Davidson telling this story, as it will likely make the scene even scarier knowing the actor's actual safety is at risk. This is some serious commitment from Davidson, who probably could have refused or asked for a double to be used. The 31-year-old might be new to the horror movie game, but he is seemingly all in and is ready to put himself in the hot seat for the sake of a good shot. It seems like this experience didn't sour things either, as the comedian has expressed interest in joining The Purge franchise. I'm here for this era, and I can't wait to see where he goes from here. You can see Pete Davidson in The Home when it hits the big screen on July 25, 2025. For more information on other exciting titles heading to the big screen this year, make sure to consult our 2025 movie schedule. Also, fans of the comedian should check out our feature on Davidson's best movies and TV shows, to see where else you can watch the actor.
Yahoo
11 minutes ago
- Yahoo
Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients
Five immunology assets in-licensed from BMS with potential to address unmet needs for patients with autoimmune diseases, including late-stage asset for lupus Bain Capital leads $300 million financing commitment PRINCETON, N.J. & BOSTON, July 28, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY, "BMS") and Bain Capital today announced the creation of a new independent biopharmaceutical company ("NewCo") focused on developing new therapies for autoimmune diseases that address significant unmet needs of patients. The newly formed company launches with five immunology assets in-licensed from BMS and a $300 million financing commitment that was led by Bain Capital. The NewCo has a broad pipeline consisting of three clinical-stage and two Phase 1-ready investigational medicines that each target promising mechanisms in autoimmune diseases. The most advanced assets in the NewCo's portfolio are afimetoran, an oral, potential best-in-class TLR7/8 inhibitor that is currently being studied in a Phase 2 clinical trial for systemic lupus erythematosus (SLE), and BMS-986322, an oral TYK2 inhibitor, which successfully established proof-of-concept in a positive plaque psoriasis Phase 2 trial. Other licensed assets include BMS-986326, a novel, potential best-in-class, IL2 fusion protein that is currently being studied in Phase 1 clinical trials for SLE and atopic dermatitis, and BMS-986481 and BMS-986498, two Phase 1-ready biologics targeting the IL18 and IL10 pathways respectively. The assets licensed to NewCo reflect the strength of BMS's scientific innovation and hold promise to address unmet needs for patients with autoimmune diseases. As part of the agreement, BMS will retain a nearly 20 percent equity stake in NewCo and will be entitled to royalties and milestones tied to the success of each asset. Robert Plenge, MD, PhD, Executive Vice President and Chief Research Officer at BMS, will also serve on NewCo's Board of Directors. This transaction reflects BMS's strategic shift in Immunology research to focus on assets that have the potential to reset the immune system and promote tissue repair. It also further demonstrates the company's sharpened strategy to invest in areas where BMS is best positioned to lead, while enabling the continued development of promising medicines. "These assets have significant potential, and we are confident that this new company will drive their development to ensure greater impact for patients," said Julie Rozenblyum, Senior Vice President, Business Development at BMS. "Bain Capital's exceptional track record in building successful life science companies by providing focused development and dedicated resources makes them ideally suited to advance these assets to realize their full promise." Daniel S. Lynch will serve as the Executive Chairman of the Company's Board of Directors and interim CEO. Mr. Lynch is an accomplished biopharmaceutical industry leader with decades of strategic, management and operational experience at companies spanning many stages of growth. Nicholas Downing, MD, Adam M. Koppel, MD, PhD, and Andrew Kaplan from Bain Capital will also join Mr. Lynch and Dr. Plenge of BMS on NewCo's Board of Directors. "We are excited to partner with BMS and we share their commitment to improving lives through science," said Adam Koppel, a Partner at Bain Capital Life Sciences. "We look forward to working together and leveraging our company creation experience to build out this new platform and advance these distinct assets in an effort to bring innovative, high-quality therapies to patients with autoimmune diseases." "This is a unique opportunity to build an innovative biotech company with a strong scientific foundation and differentiated development capabilities," said Mr. Lynch. "I'm thrilled to have the opportunity to leverage my background and experience to contribute to the success of the company as it seeks to develop much-needed new therapies, and I look forward to supporting BMS and Bain Capital in the build-out of the company's operations." Bain Capital is investing in NewCo through its Life Sciences and Private Equity teams, drawing on over 40 years of supporting the growth and innovation of healthcare companies globally. Canada Pension Plan Investment Board also joined the investment. About Bristol Myers Squibb: Transforming Patients' Lives Through ScienceAt Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information, visit us at and follow us on LinkedIn, X, YouTube, Facebook and Instagram. Bristol Myers Squibb Cautionary Statement Regarding Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products, the creation of NewCo and the agreement with NewCo. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that the expected benefits of, and opportunities related to, the creation of NewCo and the agreement with NewCo may not be realized by Bristol Myers Squibb or may take longer to realize than anticipated, that the assets described in this press release, may not achieve their primary study endpoints or receive regulatory approval for the indications described in this release in the currently anticipated timeline or at all and, if approved, whether such assets will be commercially successful. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb's business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2024, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise. About Bain CapitalFounded in 1984, Bain Capital is one of the world's leading private investment firms. We are committed to creating lasting impact for our investors, teams, businesses, and the communities in which we live. As a private partnership, we lead with conviction and a culture of collaboration, advantages that enable us to innovate investment approaches, unlock opportunities, and create exceptional outcomes. Our global platform invests across five focus areas: Private Equity, Growth & Venture, Capital Solutions, Credit & Capital Markets, and Real Assets. In these focus areas, we bring deep sector expertise and wide-ranging capabilities. We have 24 offices on four continents, more than 1,850 employees, and approximately $185 billion in assets under management. To learn more, visit Follow @BainCapital on LinkedIn and X (Twitter). corporatefinancial-news View source version on Contacts Bristol Myers Squibb Media Inquiries: media@ Investors: Bain Capital Scott Lessne / Charlyn LuskStantonslessne@ / clusk@ (646) 502-3569 / (646) 502-3549 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Washington Post
24 minutes ago
- Washington Post
To stay sharper while aging, get active, challenge your brain, and eat healthy
WASHINGTON — It's official: Older Americans worried about cognitive decline can stay sharper for longer by exercising both their bodies and their brains and eating healthier. That's according to initial results released Monday from a rigorous U.S. study of lifestyle changes in seniors at risk of developing dementia . People following a combination of healthier habits slowed typical age-related cognitive decline — achieving scores on brain tests as if they were a year or two younger, researchers reported in JAMA and at the Alzheimer's Association International Conference. It's not too late to get started -- study participants were in their 60s and 70s -- and it doesn't require becoming a pickleball champ or swearing off ice cream. 'It was the first time I felt like I was doing something proactive to protect my brain,' said Phyllis Jones, 66, of Aurora, Illinois, who joined the study after caring for her mother with dementia and struggling with her own health problems. It's too soon to know if stalling age-related decline also could reduce the risk of later Alzheimer's or other forms of dementia. But Jones and other study participants underwent brain scans and blood tests that researchers now are analyzing for clues – such as whether people also saw a reduction in Alzheimer's-related protein buildup. 'We're all on a cognitive aging clock and anything we can do to slow that clock down, to me, that is a significant benefit,' said Laura Baker of Wake Forest University School of Medicine, who led the study. Doctors have long encouraged physical activity and a healthy diet for brain fitness. Those steps fight high blood pressure and cholesterol, heart disease and diabetes, factors that increase the risk of dementia. But until now the strongest evidence that specific lifestyle changes later in life could improve how people perform on brain tests came from a study in Finland. Would it work for a more sedentary and culturally diverse U.S. population? With funding from the Alzheimer's Association and the National Institute on Aging, Baker's team tested the strategy for two years in 2,100 adults ages 60 to 79. Half of participants were randomly assigned to group classes for exercise and dietary changes plus brain-challenging homework – with peer support and coaches tracking their progress. They did a half-hour of moderately intense exercise four times a week -- plus twice a week, they added 10 to 15 minutes of stretching and 15 to 20 minutes of resistance training. They followed the 'MIND diet' that stresses lots of leafy greens and berries plus whole grains, poultry and fish. Nothing is banned but it urges limiting red meat, fried or 'fast food' and sweets, and substituting olive oil for butter and margarine. They also had to meet someone or try something new weekly and do brain 'exercises' using an online program called Brain HQ. Other study participants, the control group, received brain-healthy advice and minimal coaching — they chose what steps to follow. Both improved but the groups fared significantly better. Combining social engagement with exercise and dietary steps may be key, said Jessica Langbaum of the Banner Alzheimer's Institute, who wasn't involved with the study. 'Americans want to have that one easy thing – 'If I just eat my blueberries,'' Langbaum said. 'There is no one magic bullet. It is a whole lifestyle.' Moderately intense physical activity means raising your heart rate and panting a bit yet still able to talk, said Wake Forest's Baker. Pick something safe for your physical capability and start slowly, just 10 minutes at a time until you can handle more, she cautioned. Make it something you enjoy so you stick with it. Likewise there are many options for brain exercise, Baker said – puzzles, joining a book club, learning an instrument or a new language. Jones, a software engineer-turned-tester, learned she loves blueberry-spinach smoothies. Her favorite exercise uses an at-home virtual reality program that lets her work up a sweat while appearing to be in another country and communicating with other online users. Researchers will track study participants' health for four more years and the Alzheimer's Association is preparing to translate the findings into local community programs. Will people with stick with their new habits? Jones lost 30 pounds, saw her heart health improve and feels sharper especially when multitasking. But she hadn't realized her diet slipped when study coaching ended until a checkup spotted rising blood sugar. Now she and an 81-year-old friend from the study are helping keep each other on track. The lifestyle change 'did not just affect me physically, it also affected me mentally and emotionally. It brought me to a much better place,' Jones said. —- The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
